OpenPayments Data #3: Subsidiary Filings Prt. 2

First, some context: The requirement for direct-to-doctor (D2D) marketing transparency was enacted by Physician Payment Sunshine Act as part of ACA reforms in 2010. The call for transparency was initiated in response to concerns that D2D marketing practices by pharmaceutical & medical device companies may exert on undue influence on physician prescription practices. These concerns … Continue reading OpenPayments Data #3: Subsidiary Filings Prt. 2

OpenPayments Data #1: Activity Distributions

I’m finally getting to a point where I can start exploring CMS Open Payments data after a couple months of on-and-off tying in complementary datasets. Spoiler: There’s probably going to be a decent amount of posts following this one on pharmaceutical marketing practices. I’m starting things off with a series of visualizations of how payments … Continue reading OpenPayments Data #1: Activity Distributions